The Usefulness of Bone Metabolic Indices for the Prediction of Changes in Bone Mineral Density after Parathyroidectomy in Patients with Primary Hyperparathyroidism

 

 Buy Article Permissions and Reprints

Abstract

Patients with primary hyperparathyroidism (pHPT) have reduced bone mineral density (BMD). Although pHPT causes high bone turnover, the exact metabolic bone markers useful for predicting changes in BMD after parathyroidectomy (PTX) remain elusive. The present study was performed to examine the relationship between bone metabolic indices and BMD changes after PTX in 29 pHPT Japanese patients, which received PTX successfully. BMD values were measured by dual-energy X-ray absorptiometry in the lumbar spine and distal one third of radius. As for bone metabolic indices, serum bone-type alkaline phosphates (BAP), serum osteocalcin (OCN), urinary deoxypiridinoline (Dpd), and urinary type I collagen cross-linked N-telopeptides (NTX) were measured. The study included 10 male and 19 female patients (17 postmenopausal). Urinary Dpd, but not NTX was significantly correlated with serum BAP and OCN. Either bone formation or bone resorption indices were significantly and highly correlated with Z-score of BMD in the radius, but not at lumbar spine. Urinary Dpd was significantly correlated with BMD changes at both lumbar spine and radius and at all time points over the two years after PTX. These correlations were most potent among bone metabolic indices in this study. The measurement of urinary Dpd would be useful for predicting long-term changes in BMD at radial and lumbar spine after PTX than other bone metabolic indices.

References

• 1 Silverberg S J, Shane E, De La Cruz L, Dempster D W, Feldman F, Seldin D, Jacobs T P, Siris E S, Cafferty M, Parisien M V. Skeletal disease in primary hyperparathyroidism.  J Bone Miner Res. 1989;  4 283-291
  PubMedGoogle Scholar
• 2 Silverberg S J, Locker F G, Bilezikian J P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism.  J Clin Endocrinol Metab. 1996;  81 4007-4012
  CrossrefPubMedGoogle Scholar
• 3 Dempster D W, Parisien M, Silverberg S J, Liang X G, Schnitzer M, Shen V, Shane E, Kimmel D B, Recker R, Lindsay R, Bilezikian J P. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism.  J Clin Endocrinol Metab. 1999;  84 1562-1566
  CrossrefPubMedGoogle Scholar
• 4 Nakaoka D, Sugimoto T, Kobayashi T, Yamaguchi T, Kobayashi A, Chihara K. Prediction of bone mass change after parathyroidictomy in patients with primary hyperparathyroidism.  J Clin Encocrinol Metab. 2000;  85 1901-1907
  CrossrefPubMedGoogle Scholar
• 5 Melton III L J, Atkinson E J, O’Fallon W M, Heath III H. Risk of age-related fractures in patients with primary hyperparathyroidism.  Arch Intern Med. 1992;  152 2269-2273
  CrossrefPubMedGoogle Scholar
• 6 Kenny A M, MacGillivray D C, Pilbeam C C, Crombie H D, Raisz L G. Fracture incidence in postmenopausal women with primary hyperparathyroidism.  Surgery. 1995;  118 109-114
  PubMedGoogle Scholar
• 7 Kohsla S, Melton III L J, Wermers R A, Crowson C S, O’Fallon W M, Riggs B L. Primary hyperparathyroidism and risk of fracture: a population-based study.  J Bone Miner Res. 1999;  14 1700-1707
  CrossrefPubMedGoogle Scholar
• 8 Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism.  Eur J Endocrinol. 2005;  153 373-378
  CrossrefPubMedGoogle Scholar
• 9 Chen Q, Kaji H, Iu M F, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects.  J Clin Endocrinol Metab. 2003;  88 2655-2658
  PubMedGoogle Scholar
• 10 Silverberg S J, Gartenberg F, Jacobs T P, Shane E, Siris E, Staron R B, McMahon D J, Bilezikian J P. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism.  J Clin Endocrinol Metab. 1995;  80 729-734
  CrossrefPubMedGoogle Scholar
• 11 Silverberg S L, Shane E, Jacobs T P, Siris E, Bilezikian J P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.  New Engl J Med. 1999;  341 1249-1255
  CrossrefPubMedGoogle Scholar
• 12 Nomura R, Sugimoto T, Tsukamoto T, Yamauchi M, Sowa H, Chen Q, Yamaguchi T, Kobayashi A, Chihara K. Marked and sustained increase in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism in patients with primary hyperparathyroidism; a six-year longitudinal study with or without parathyroidectomy in a Japanese population.  Clin Endocrinol. 2004;  60 335-342
  CrossrefPubMedGoogle Scholar
• 13 Yano S, Sugimoto T, Tsukamoto T, Yamaguchi T, Hattori T, Sekita K, Kaji H, Hattori S, Kobayashi A, Chihara K. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain.  Horm Metab Res. 2003;  35 259-264
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Seibel M J, Gartenberg F, Silverberg S J, Ratcliffe A, Robins S P, Bilezikian J P. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism.  J Clin Endocrinol Metab. 1992;  74 481-486
  CrossrefPubMedGoogle Scholar
• 15 Minisola S, Rosso R, Romagnoli E, Pacitti M T, Scarnecchia L, Carnevale V, Mazzuoli G. Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover.  Bone Miner. 1993;  20 113-123
  PubMedGoogle Scholar
• 16 Chen Q, Kaji H, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Yamaguchi T, Kobayashi A, Sugimoto T, Chihara K. Trial to predict malignancy of affected parathyroid glands in primary hyperparathyroidism.  Endocr J. 2003;  50 527-534
  CrossrefPubMedGoogle Scholar
• 17 Grey A, Mitnick M, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-α are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-a clinical research center study.  J Clin Endocrinol Metab. 1996;  81 3450-3454
  CrossrefPubMedGoogle Scholar
• 18 Nakchbandi I A, Mitnick M A, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism.  J Clin Endocrinol Metab. 2002;  87 4946-4951
  CrossrefPubMedGoogle Scholar
• 19 Behr W, Barnert J. Quantification of bone alkaline phophatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility.  Clin Chem. 1986;  32 1960-1966
  PubMedGoogle Scholar
• 20 Garton M, Martin J, Stewart A, Krukowski Z, Matheson N, Robins S, Loveridge N, Reid D. Changes in bone mass and metabolism after surgery for primary hyperparathyroidism.  Clin Endocrinol. 1995;  42 493-500
  CrossrefPubMedGoogle Scholar
• 21 Guo C Y, Thomas W E, AlDehami A W, Assiri A M, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.  J Clin Endocrinol Metab. 1996;  81 3487-3491
  CrossrefPubMedGoogle Scholar
• 22 Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L, Mosekilde L. Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy.  Bone. 1999;  25 237-244
  CrossrefPubMedGoogle Scholar
• 23 Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L, Mosekilde L. Primary hyperparathyrodism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study.  Bone. 1999;  25 589-595
  CrossrefPubMedGoogle Scholar
• 24 Sugimoto T, Kaji H, Nakaoka D, Yamauchi M, Yano S, Sugishita T, Baylink D J, Mohan S, Chihara K. Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis.  Eur J Endocrinol. 2002;  147 339-348
  PubMedGoogle Scholar
• 25 Hanson D A, Weis M A, Bollen A M, Maslan S L, Singer F R, Eyre D R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.  J Bone Miner Res. 1992;  7 1251-1258
  PubMedGoogle Scholar
• 26 Iida-Klein A, Zhou H, Lu S S, Levine L R, Ducayen-Knowles M, Dempster D W, Nieves J, Lindsay R. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.  J Bone Miner Res. 2002;  17 808-816
  CrossrefPubMedGoogle Scholar
• 27 Ryder K D, Duncan R L. Parathyroid hormone modulates the response of osteoblast-like cells to mechanical stiumulation.  Calcif Tissue Int. 2000;  67 241-246
  CrossrefPubMedGoogle Scholar
• 28 Taguchi Y, Gorai I, Zhang M G, Chaki O, Nakayama M, Minaguchi H. Differences in bone resorption after menopause in Japanese women with normal or low bone mineral density: quantitation of urinary cross-linked N-telopeptides.  Calif Tissue Int. 1998;  62 395-399
  PubMedGoogle Scholar
• 29 Braga de Castro Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis.  J Bone Miner Res. 1999;  14 602-608
  CrossrefPubMedGoogle Scholar
• 30 Lumachi F, Ermani M, Basso S M, Camozzi V, Nardi A, Favia G, Luisetto G. Short- and long-term changes in bone mineral density of the lumbar spine after parathyroidectomy in patients with primary hyperparathyroidism.  Calcif Tissue Int. 2003;  73 44-48
  CrossrefPubMedGoogle Scholar

Hiroshi Kaji, M. D.

Division of Endocrinology/Metabolism, Neurology and Hematology/Oncology, Department of Clinical Molecular Medicine

Kobe University Graduate School of Medicine · 7-5-1 Kusunoki-cho · Chuo-ku · Kobe 650-0017 · Japan

Phone: +81 (78) 382-5885

Fax: +81 (78) 382-5899 ·

Email: hiroshik@med.kobe-u.ac.jp